(Q57781473)

English

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695951%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695951%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

0 references

corrigendum / erratum

Erratum to: Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

0 references

Diana Giannarelli

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695951%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Antonio M Grimaldi

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695951%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Corrado Caracò

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695951%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Assunta Esposito

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695951%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695951%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Antonella Petrillo

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695951%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695951%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Franco Fulciniti

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695951%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Giuseppe Palmieri

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695951%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695951%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Paolo Marchetti

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695951%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Virginia Ferraresi

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695951%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Maria Pia Pistillo

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695951%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Gennaro Ciliberto

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695951%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Paolo Antonio Ascierto

23

object named as

Paolo A Ascierto

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695951%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1

object named as

Ester Simeone

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695951%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Nicola Mozzillo

22

object named as

Nicola Mozzillo

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695951%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Giusy Gentilcore

2

object named as

Giusy Gentilcore

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695951%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Marcello Curvietto

6

object named as

Marcello Curvietto

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695951%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

8

object named as

Miriam Paone

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695951%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Ernesta Cavalcanti

10

object named as

Ernesta Cavalcanti

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695951%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Fabio Sandomenico

11

object named as

Fabio Sandomenico

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695951%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

author name string

Gaetana Rinaldi

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695951%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

publication date

3 April 2014

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695951%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695951%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

63

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695951%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695951%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

675-683

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695951%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

https://scigraph.springernature.com/pub.10.1007/s00262-014-1545-8

0 references

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1545-8

21 January 2018

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1545-8

21 January 2018

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1545-8

21 January 2018

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1545-8

21 January 2018

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1545-8

21 January 2018

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1545-8

21 January 2018

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1545-8

21 January 2018

Prognostic versus predictive value of biomarkers in oncology.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1545-8

21 January 2018

Defining the critical hurdles in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1545-8

21 January 2018

Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1545-8

21 January 2018

Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1545-8

21 January 2018

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1545-8

21 January 2018

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1545-8

21 January 2018

Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1545-8

21 January 2018

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1545-8

21 January 2018

Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1545-8

21 January 2018

Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1545-8

21 January 2018

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1545-8

21 January 2018

Biomarkers on melanoma patient T cells associated with ipilimumab treatment

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1545-8

21 January 2018

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1545-8

21 January 2018

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1545-8

21 January 2018

Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1545-8

21 January 2018

Final version of 2009 AJCC melanoma staging and classification

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1545-8

21 January 2018

Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1545-8

21 January 2018

Identifiers

10.1007/S00262-014-1545-8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695951%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24695951%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57781473&oldid=1998095745"